Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)
Public ClinicalTrials.gov record NCT02631044. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)
Study identification
- NCT ID
- NCT02631044
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Juno Therapeutics, a Subsidiary of Celgene
- Industry
- Enrollment
- 387 participants
Conditions and interventions
Conditions
Interventions
- JCAR017 (lisocabtagene maraleucel) 2-dose schedule Biological
- JCAR017 (lisocabtagene maraleucel) single-dose schedule Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 5, 2016
- Primary completion
- May 15, 2024
- Completion
- May 15, 2024
- Last update posted
- Jun 26, 2024
2016 – 2024
United States locations
- U.S. sites
- 14
- U.S. states
- 12
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0006 | Birmingham | Alabama | 35294 | — |
| Local Institution - 0007 | Duarte | California | 91010-300 | — |
| Local Institution - 0010 | San Francisco | California | 94143-0372 | — |
| Local Institution - 0020 | Aurora | Colorado | 80045 | — |
| Local Institution - 0019 | Atlanta | Georgia | 30342 | — |
| Local Institution - 0003 | Chicago | Illinois | 60611 | — |
| Local Institution - 0005 | Boston | Massachusetts | 02114 | — |
| Local Institution - 0015 | Boston | Massachusetts | 02115 | — |
| Local Institution - 0008 | Omaha | Nebraska | 68198-7680 | — |
| Local Institution - 0001 | New York | New York | 10065 | — |
| Local Institution - 0021 | Charlotte | North Carolina | 28204 | — |
| Local Institution - 0029 | Pittsburgh | Pennsylvania | 15232 | — |
| Local Institution - 0002 | Houston | Texas | 77030 | — |
| Local Institution - 0018 | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02631044, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 26, 2024 · Synced May 14, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02631044 live on ClinicalTrials.gov.